

Special Issue

Advances in Pediatric Cancer Therapy

Message from the Guest Editors

Progress in pediatric hematology and oncology is correlated to the identification of clinical and biologic prognostic factors, leading to risk-adapted therapeutic approaches with treatment intensity modulated to the molecular characteristics at diagnosis as well as to the response in the treatment course. The risk of late effects associated with intensive treatment are widely recognized. Hence, new therapeutic approaches combining less intensive chemotherapy and innovative treatments are under investigation with the aim to increase overall survival and minimize late mortality and side effects. Advances in the understanding of the genetics of pediatric cancer have allowed the identification of molecular targets that can potentially be exploited for therapeutic benefits. Many novel agents that target specific genetic lesions are under evaluation in subgroups of relapsed/refractory patients in prospective clinical trials and retrospective series. Other therapeutic approaches characterized by immunotherapeutic strategies, e.g. monoclonal antibodies, BiTEs and CAR T-cells, are improving remission rates in refractory/relapsed disease, and are under evaluation in first-line settings.

Guest Editors

Dr. Luciana Vinti

Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

Dr. Maria Antonietta De Ioris

Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

Deadline for manuscript submissions

closed (30 November 2022)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/105458

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).